Segment Information

3 Months Ended

Mar. 31, 2022

Segment Information

Segment Information

Note 11. Segment Information

The Company operates as one segment, regenerative medicines. The segment is based on financial information that is utilized by the Company’s Chief Operating Decision Maker (“CODM”), who is the Company’s Chief Executive Officer, to assess performance and allocate resources.

For the three months ended March 31, 2022 and 2021, the Company’s net sales disaggregated by the major sources - Core Products and Non-Core Products (see Note 1) - were as follows (in thousands):

	Three Months Ended
	March 31,
	2022		2021
Sales by product
Core Products	$	8,140	$	10,664
Non-Core Products		3,355		2,220
Total Net Sales	$	11,495	$	12,884